Physician profile
Robert A Moore
NPI 1245241124
$5,430.17
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,121 · 2020: $1,824 · 2021: $1,396 · 2022: $1,053 · 2023: $37.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $37.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $37.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,119.86 | 2019-2023 | Proclaim |
| Boston Scientific Corporation | $679.73 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $446.58 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $267.81 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $213.23 | 2019-2021 | |
| Nevro Corp. | $140.13 | 2021 | |
| Grt US Holding, INC. | $133.86 | 2021-2022 | |
| Amgen INC. | $121.74 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $117.42 | 2019-2022 | |
| Sentynl Therapeutics, INC. | $112.18 | 2019 | |
| Acumed LLC | $104.41 | 2022 | |
| Fujifilm Sonosite, INC. | $92.40 | 2019 | |
| Daiichi Sankyo INC. | $86.97 | 2019 | |
| Avanos Medical | $83.16 | 2019-2020 | |
| Horizon Therapeutics Plc | $81.58 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $74.96 | 2020-2022 | |
| Zyla Life Sciences, INC. | $73.39 | 2019-2020 | |
| Virtus Pharmaceuticals LLC | $51.71 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $49.45 | 2019 | |
| Arbor Pharmaceuticals, INC. | $41.11 | 2019-2021 | |
| Shionogi INC | $37.44 | 2019 | |
| Almatica Pharma LLC | $30.28 | 2021 | |
| Medtronic USA, INC. | $29.89 | 2019 | |
| Nalu Medical, INC. | $27.50 | 2022 | |
| Depuy Synthes Sales INC. | $26.16 | 2019-2020 | |
| Pacira Therapeutics, INC. | $25.45 | 2020 | |
| Assertio Therapeutics, INC. | $25.07 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $22.87 | 2021 | |
| Pfizer INC. | $22.50 | 2019 | |
| Innovation Technologies INC | $17.89 | 2023 | Irrisept |
| Kowa Pharmaceuticals America, INC. | $16.84 | 2022 | |
| Redhill Biopharma INC. | $16.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.90 | 2021 | |
| Lilly USA, LLC | $13.56 | 2020 | |
| Pernix Therapeutics Holdings, INC. | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.